Literature DB >> 23211301

Expression and release of leptin and proinflammatory cytokines in patients with ulcerative colitis and infectious diarrhea.

G Biesiada1, J Czepiel, A Ptak-Belowska, A Targosz, G Krzysiek-Maczka, M Strzalka, S J Konturek, T Brzozowski, T Mach.   

Abstract

Leptin plays not only an important role in regulation of food intake, but also in the mechanism of inflammation. The universal presence of leptin in the cells of immune system and its secretion by these cells caused increasing interest in the role of this hormone in ulcerative colitis (UC). We determined the role of leptin in 80 patients, aged from 18 to 69 years, including 50 patients with active UC and 30 patients with infectious diarrhea. The tests were performed within 48 hours of the first symptoms, in the period of remission of UC and 8 weeks after resolution of infectious diarrhea. Endoscopy was performed in each patient, and the biopsy samples were taken for the assessments of expression of mRNA for leptin, IL-1β, IL-6 and TNF-α by RT-PCR and Western blot. Blood tests included concentrations of leptin, IL-1β, IL-6 and TNF-α. In addition, the plasma levels of leptin, IL-1β, IL-6 and TNF-α were assessed by ELISA. Serum concentrations of leptin was significantly increased in patients with exacerbation of UC over that in patients with UC in remission. The serum leptin concentration was significantly higher in patients with infectious diarrhea, than the patients that recovered from infectious diarrhea. The leptin protein was overexpressed in the biopsy samples of the mucosa of large intestine compared to those with exacerbation of UC, and in patients after successful recovery from infectious diarrhea. The leptin mRNA was overexpressed in patients with infectious diarrhea compared with that in the group of patients after successful recovery from this condition. Serum concentrations of leptin failed to correlate with severity of exacerbation of UC and with extent of intestinal inflammatory lesions in patients with UC. However, the correlation was observed between serum concentrations of leptin in patients with exacerbation of UC and serum concentrations of proinflammatory cytokines IL-1β and TNF-α. We conclude that 1) the increased leptin in exacerbated UC is related to the increased serum proinflammatory cytokines IL-1β, TNF-α and IL-6 levels; 2) In patients with infectious diarrhea, the concentrations of leptin in intestinal mucosa correlates with serum concentrations of cytokines IL-1β, IL-6 and TNF-α and with an increased expression of leptin mRNA in intestinal mucosa but not with alterations in serum levels of this hormone; 3) leptin may serve as useful predictive marker of inflammation in inflammatory bowel disease (IBD).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23211301

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  24 in total

Review 1.  Scleroderma-related lung disease: are adipokines involved pathogenically?

Authors:  Shannon Haley; Dilip Shah; Freddy Romero; Ross Summer
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

2.  High-fat diet induced leptin and Wnt expression: RNA-sequencing and pathway analysis of mouse colonic tissue and tumors.

Authors:  Harrison M Penrose; Sandra Heller; Chloe Cable; Hani Nakhoul; Melody Baddoo; Erik Flemington; Susan E Crawford; Suzana D Savkovic
Journal:  Carcinogenesis       Date:  2017-03-01       Impact factor: 4.944

Review 3.  Possible mechanisms of action of mushroom-derived glucans on inflammatory bowel disease and associated cancer.

Authors:  Betty Schwartz; Yitzhak Hadar
Journal:  Ann Transl Med       Date:  2014-02

4.  Role of leptin-mediated colonic inflammation in defense against Clostridium difficile colitis.

Authors:  Rajat Madan; Xiaoti Guo; Caitlin Naylor; Erica L Buonomo; Donald Mackay; Zannatun Noor; Patrick Concannon; Kenneth W Scully; Patcharin Pramoonjago; Glynis L Kolling; Cirle A Warren; Priya Duggal; William A Petri
Journal:  Infect Immun       Date:  2013-10-28       Impact factor: 3.441

Review 5.  The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease.

Authors:  Udai P Singh; Narendra P Singh; Hongbing Guan; Brandon Busbee; Robert L Price; Dennis D Taub; Manoj K Mishra; Raja Fayad; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Int Rev Immunol       Date:  2013-07-10       Impact factor: 5.311

6.  Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides.

Authors:  Olga Y Korolkova; Jeremy N Myers; Samuel T Pellom; Li Wang; Amosy E M'Koma
Journal:  Clin Med Insights Gastroenterol       Date:  2015-05-06

Review 7.  Stress & the gut-brain axis: Regulation by the microbiome.

Authors:  Jane A Foster; Linda Rinaman; John F Cryan
Journal:  Neurobiol Stress       Date:  2017-03-19

Review 8.  Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases.

Authors:  Wan Sun; Richard A Lirio; Jennifer Schneider; Jiri Aubrecht; Harisha Kadali; Mike Baratta; Parul Gulati; Ajit Suri; Tiffany Lin; Raghavan Vasudevan; Maria Rosario
Journal:  Clin Pharmacol Drug Dev       Date:  2020-12-16

Review 9.  The role of physical exercise in inflammatory bowel disease.

Authors:  Jan Bilski; Bartosz Brzozowski; Agnieszka Mazur-Bialy; Zbigniew Sliwowski; Tomasz Brzozowski
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.411

10.  Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis.

Authors:  Xiaohui Wei; Jane R Kenny; Leslie Dickmann; Romeo Maciuca; Caroline Looney; Meina T Tang
Journal:  J Clin Pharmacol       Date:  2016-01-11       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.